Share our Vision

CDR-Life has formed a successful partnership with Boehringer Ingelheim, bringing together our antibody fragment expertise with Boehringer’s clinical development and marketing expertise. Boehringer Ingelheim has announced the intention to move the program forward into Phase 2 clinical testing.

We are open to partnering with companies, academic collaborators and individuals who share our vision and can help bring CDR-Life’s innovations to patients. Our unique M-gager® platform can deliver attractive clinical candidates in a matter of months, which provides an excellent basis for R&D collaborations on novel targets.

Our team has a substantial track record in both forming and working in partnerships between pharma and biotech companies to bring new therapeutics to market for patients.